GENERIC NAME: bimatoprost
BRAND NAME: Latisse, Lumigan
DRUG CLASS AND MECHANISM: Bimatoprost is a synthetic (man-made) drug that resembles and mimics the effects of natural chemicals (prostaglandins) produced by the body and is used for reducing intraocular pressure (IOP) and increasing the growth of eyelashes. The exact mechanism of action is unknown. Bimatoprost may reduce IOP by increasing the outflow of aqueous humor from the eye of individuals with narrow angle glaucoma. Excessive aqueous humor may cause optic nerve damage and visual loss. It may increase eyelash growth by increasing the duration of the growing phase of the eyelash.
The FDA approved Lumigan in March 2001 and Latisse in December 2008.
SIDE EFFECTS: Common side effects include:
- Itching of the eyes
- Growth of eyelashes
- Eye irritation
- Dry eyes
- Eye redness
- Eye lash darkening and reversible darkening of skin around the eyes
Bimatoprost may also cause permanent brown pigmentation in the colored part of the eye and hair growth in other areas of the body that it comes in contact with.
GENERIC AVAILABLE: No
PREPARATIONS: Solution (eye drops): 0.01% and 0.03%
STORAGE: S Solutions should be store at 2 C to 25 C (36 F to 77 F).
DOSING: The recommended dosage of bimatoprost for reducing IOP is one drop of Lumigan 0.01 or 0.03% in the affected eye(s) once daily in the evening. More frequent administration may reduce the IOP-reducing effect. Reduction in IOP starts approximately four hours after administration and maximum effect occurs in approximately 8 to 12 hours.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.